Antithrombotic Therapy


The Practical Cardiology™ Antithrombotic Therapy clinical resource center offers updates and information about the latest in the fields of antiplatelet and anticoagulation therapy. On this page you will find content related to FDA approvals and the latest information for preventing thrombosis in the form of articles, video interviews with leading experts, clinician-authored columns, and more.

Rivaroxaban Bests Combination Therapy for Total Event, Mortality Risk in Stable CAD with AFib

June 16, 2022

A secondary analysis of the AFIRE trial provides further detail on the reduction in event risk and mortality associated with rivaroxaban monotherapy compared to combination therapy in patients with atrial fibrillation and stable coronary artery disease.

Early Aspirin Use Could Lower Mortality, Odds of Stroke in COVID-19

March 24, 2022

An analysis of data from more than 110k hospitalized patients with COVID-19 suggests aspirin use on the first day of hospitalization was linked to lower odds for both in-hospital mortality and pulmonary embolism in weighted analyses.

Antiplatelet Therapy Unlikely to Improve Organ Support-Free Days in COVID-19

March 23, 2022

Data from the REMAP-CAP trial suggests use of aspirin or P2Y12 inhibitors had a low likelihood of improving organ support-free days in critically ill patients with COVID-19 within 21 days compared to no antiplatelet therapy.

DOACs Could Lower Bleeding, Hemorrhage Risk vs. Warfarin in Patients with CVT

February 10, 2022

An international, retrospective analysis presented at ISC 2022 provides evidence suggesting use of DOACs as a treatment for cerebral venous thrombosis was associated with similar risk of recurrent clots and death as warfarin, but a 65% lower risk of major bleeding.